WaveMan
WaveMan · Company
NRIX · Nurix Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

NRIX Nurix Therapeutics (NRIX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001549595
Quote by TradingView
Form 144 · 7
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
110
13F, latest reported quarter
Conversions, 180 days
21
Codes C/M, not in net · $506.3K priced

What the filings say about NRIX

Insiders, 180 days
-$3.4M net sold
4 sellers · 22% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.6M
7 notices

Nurix Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Nurix Therapeutics, Inc. insiders sold a net $3.4M of stock across 150 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Hansen Gwenn
Chief Scientific Officer
SELL
2026-10-15 SEC
1,452
$36.3K
+4.6%
Context
  • 34 earlier Form 4 trades (code P or S) here by this insider (34 sales), the last on Sep 1, 2026.
  • The trade is 1.2% of the 117,227 shares held after it.
  • 2 other insiders sold within 30 days.
  • 110 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Hansen Gwenn sold about $36.3K of NRIX under a 10b5-1 plan on Oct 15, 2026; 2 other insiders sold within 30 days and 110 funds added in the latest 13F quarter.
GREGORY JULIA P
Director
SELL
2026-10-14 SEC
22,583
$528.5K
+2.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 210.1% of the 10,750 shares held after it.
  • 2 other insiders sold within 30 days.
  • 110 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director GREGORY JULIA P sold about $528.5K of NRIX on Oct 14, 2026; 2 other insiders sold within 30 days and 110 funds added in the latest 13F quarter.
Ring Christine
Chief Legal Officer
SELL
2026-10-02 SEC
5,786
$134.1K
+11.7%
Context
  • 66 earlier Form 4 trades (code P or S) here by this insider (66 sales), the last on Sep 2, 2026.
  • The trade is 63.5% of the 9,110 shares held after it.
  • 2 other insiders sold within 30 days.
  • 110 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Ring Christine sold about $134.1K of NRIX under a 10b5-1 plan on Oct 2, 2026; 2 other insiders sold within 30 days and 110 funds added in the latest 13F quarter.
Ring Christine
Chief Legal Officer
SELL
2026-09-02 SEC
5,387
$138.4K
+0.9%
Context
  • 64 earlier Form 4 trades (code P or S) here by this insider (64 sales), the last on Aug 3, 2026.
  • The trade is 56.6% of the 9,510 shares held after it.
  • 2 other insiders sold within 30 days.
  • 110 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Ring Christine sold about $138.4K of NRIX under a 10b5-1 plan on Sep 2, 2026; 2 other insiders sold within 30 days and 110 funds added in the latest 13F quarter.
Ring Christine
Chief Legal Officer
SELL
2026-09-02 SEC
400
$10.7K
+0.9%
Context
  • 64 earlier Form 4 trades (code P or S) here by this insider (64 sales), the last on Aug 3, 2026.
  • The trade is 4.4% of the 9,110 shares held after it.
  • 2 other insiders sold within 30 days.
  • 110 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Ring Christine sold about $10.7K of NRIX under a 10b5-1 plan on Sep 2, 2026; 2 other insiders sold within 30 days and 110 funds added in the latest 13F quarter.
150 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 145 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$3.4M over 180 days
-$1.8M over 90 days
below 75% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
110 funds bought in last quarter
more than 72% of Pharma & Biotech
Revenue
+54.0% year over year
more than 78% of Pharma & Biotech
Margin
-314.9% net margin
below 72% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
25.9% of the float short (float per yahoo 2026-10-27) · 9.2 days to cover · settled 2026-10-15
more than 92% of Pharma & Biotech
What changed in the last 30 days
Oct 15Chief Scientific Officer Hansen Gwenn sold $36.3K under a 10b5-1 plan (Oct 15)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 14Director JULIA GREGORY filed to sell $528.5K by Oct 14 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 14Director GREGORY JULIA P sold $528.5K (Oct 14)
Oct 2Officer CHRISTINE RING filed to sell $135.0K by Oct 2 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 2Chief Legal Officer Ring Christine sold $134.1K under a 10b5-1 plan (Oct 2)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.

Watch NRIX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+145.7%12M
+0%+56%+111%+167%2025-102025-122026-022026-042026-062026-082026-10 2025-11-24 · Ring Christine sold $641.8K2026-06-25 · Ring Christine sold $580.4K2026-10-14 · GREGORY JULIA P sold $528.5K2026-08-03 · Ring Christine sold $382.4K2026-07-02 · Ring Christine sold $259.4K2026-02-09 · Ring Christine sold $237.6K2026-05-05 · van Houte Hans sold $223.4K2026-09-02 · Ring Christine sold $138.4K2026-05-04 · Ring Christine sold $138.2K2026-06-02 · Ring Christine sold $135.3K2026-10-02 · Ring Christine sold $134.1K2026-03-02 · Ring Christine sold $125.8K2026-04-02 · Ring Christine sold $124.2K2026-08-05 · Hansen Gwenn sold $108.9K2026-06-25 · Hansen Gwenn sold $107.9K2026-05-01 · Ring Christine sold $90.4K2026-07-30 · Hansen Gwenn sold $90.0K2026-07-30 · Ring Christine sold $90.0K2026-01-30 · Hansen Gwenn sold $79.5K2025-11-03 · van Houte Hans sold $78.9K2026-08-04 · van Houte Hans sold $73.1K2026-01-30 · Ring Christine sold $71.8K2026-01-20 · Ring Christine sold $69.3K2026-07-30 · van Houte Hans sold $66.5K2026-08-04 · Hansen Gwenn sold $64.3K2025-12-18 · Ring Christine sold $63.6K2026-01-30 · van Houte Hans sold $59.5K2026-04-30 · Ring Christine sold $53.5K2026-04-30 · Hansen Gwenn sold $53.5K2025-10-30 · Hansen Gwenn sold $52.3K2025-10-30 · Ring Christine sold $46.6K2026-08-04 · van Houte Hans sold $42.9K2025-10-30 · van Houte Hans sold $40.1K2026-04-30 · van Houte Hans sold $39.8K2026-09-01 · Hansen Gwenn sold $37.0K2026-10-15 · Hansen Gwenn sold $36.3K2026-08-04 · Hansen Gwenn sold $35.8K2026-09-02 · Ring Christine sold $10.7K2026-05-05 · van Houte Hans sold $10.0K2025-12-18 · Ring Christine sold $3.7K2026-01-30 · Hansen Gwenn sold $1.7K2026-01-30 · Ring Christine sold $1.5K2026-10-14 · JULIA GREGORY filed to sell $528.5K2026-10-02 · CHRISTINE RING filed to sell $135.0K2026-09-02 · CHRISTINE RING filed to sell $150.7K2026-08-05 · GWENN HANSEN filed to sell $215.1K2026-08-04 · GWENN M HANSEN filed to sell $95.5K2026-08-04 · JOHANNES VAN HOUTE filed to sell $110.6K2026-08-03 · CHRISTINE RING filed to sell $385.0K2026-07-02 · CHRISTINE RING filed to sell $263.2K2026-06-25 · GWENN M HANSEN filed to sell $104.1K2026-06-25 · CHRISTINE RING filed to sell $558.4K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NRIX: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
8,770,349 sh
$212.8M
Vestal Point Capital, LP
8,050,000 sh
$195.3M
Deep Track Capital, LP
7,736,455 sh
$187.7M
Rubric Capital Management LP
7,227,778 sh
$175.3M
FMR LLC
5,485,215 sh
$133.1M

Congress trades in NRIX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NRIX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
JULIA GREGORY
Filed 2026-10-14
$528.5K
CHRISTINE RING
Filed 2026-10-02
$135.0K
CHRISTINE RING
Filed 2026-09-02
$150.7K
GWENN HANSEN
Filed 2026-08-05
$215.1K
GWENN M HANSEN
Filed 2026-08-04
$95.5K

NRIX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ARK Genomic Revolution ETF
$39.0M position · as of 2026-07-31
2.5%
Eventide Healthcare & Life Sciences Fund
$31.5M position · as of 2026-06-30
1.8%
Global X HealthTech ETF
$406.2K position · as of 2026-05-31
1.6%
AlphaCentric Life Sciences and Healthcare Fund
$627.0K position · as of 2026-06-30
1.3%
Virtus Biotech Clinical Trials Etf
$425.6K position · as of 2026-07-31
0.9%
WesMark Small Company Fund
$1.5M position · as of 2026-06-30
0.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
10 registered trials, 6 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
7
Phase 1
3 active
1
Phase 2
1 active
1
Phase 3
1 active
1
Multi-phase
1 active
What changed recently
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
2026-09-01 · Not Yet Recruiting → Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $3.4M sold by insiders over 180 days, 110 funds added last quarter, $1.6M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

NRIX financials

Revenue growth
+54.0%
XBRL, annual
Net margin
-314.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$701.9M
four quarters, 2025-09-01 to 2026-08-31
Net margin, TTM
+42.0%
net income over revenue, 2025-09-01 to 2026-08-31
Free cash flow, TTM
$369.8M
operating cash flow minus capex, 2025-09-01 to 2026-08-31
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
+44.0%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on assets
+34.3%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
+38.5%
operating income (EBIT proxy) over average of 2025-08-31 and 2026-08-31 minus current liabilities
P/E, trailing
11.11x
close 2026-10-26 over four quarters of diluted EPS, 2025-09-01 to 2026-08-31
Enterprise value
n/a
no debt line filed
FCF yield
+13.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-112024-112023-112022-11
Revenue$84.0M$54.5M$77.0M$38.6M
Operating income-$285.7M-$213.0M-$155.1M-$183.9M
Net income-$264.5M-$193.6M-$143.9M-$180.4M
EPS (diluted)-3.05-2.88-2.65-3.71
Operating cash flow-$249.5M-$172.6M-$81.4M-$159.8M
Cash$247.0M$110.0M$54.6M$64.5M
SEC XBRL, fiscal years, as known on 2026-10-28

NRIX Stock Sonar score 5/7 axes

Find similar shapesCompare

NRIX ranks highest on profitability (95th percentile) and growth (78th), and lowest on insider conviction (12th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
95
Inputs
  • Return on equity+44.0% · 94 pct, sector of 545
  • Return on assets+34.3% · 94 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed+38.5% · 98 pct, sector of 576
Growth
78
Inputs
  • Revenue growth, YoY+54.0% · 78 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
12
Inputs
  • Net Form 4 buying (codes P and S), 180d-$3.0M · 24 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
72
Inputs
  • Funds adding, latest quarter110 · 72 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
42
Inputs
  • Short interest, % of float+25.9% · 7 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+6.2% · 77 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NRIX filings, in plain words

Are Nurix Therapeutics insiders buying or selling NRIX?

In the 180 days to 2026-10-28, Nurix Therapeutics insiders were net sellers, a net $3.4M across purchases and sales reported on Form 4, by 4 sellers.

Are there planned insider sales of NRIX?

Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.6M of stock; the latest, by JULIA GREGORY, was filed 2026-10-14.

Read the full summary

In the 180 days to 2026-10-28, Nurix Therapeutics insiders were net sellers of NRIX, a net $3.4M across purchases and sales reported on Form 4 by 4 sellers. 22% of the 23 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.6M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies